|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
NOVEMBER 22, 2004
By Gene G. Marcial Diomed Could Get A Boost From Medicare  Diomed Holdings (DIO
), a small medical-device maker, is bound to become a big player in laser removal of varicose veins. So say some investors who bought shares as they fell from 4 in June to 2.59 now. The stock hit 9 in February but collapsed soon after venture capitalists took profits on shares they bought cheap as part of a private financing. Diomed's patented EndoVenous Laser Treatment has grown fast -- and should pick up with 2005's increased Medicare coverage, announced on Nov. 4, for removing varicose veins.
"Doctors will be reimbursed at $2,041 for the first vein and $437 for each additional one," says Paul Yook of Sedna Capital Management, which owns shares. Eric Sandler, of research boutique Sandler, who rates the stock a buy, has a 12-month target of 8. Diomed's Food & Drug Administration-approved procedure involves inserting a fiber-optic catheter into the faulty vein, which is then removed by laser. No anesthesia is needed. Diomed sells the laser system for $30,000, with a $300 procedure kit. It also collects a fee on each treatment. Yook figures Diomed will lose money this year and next -- but earn 60 cents a share in 2006 on sales of $42 million, vs. a forecast $25 million in 2005. Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  See Gene on Fridays at 1:20 p.m. EST on CNNfn's The Money Gang. Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2004, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version
